Zhang Y, Zhou W, Yang J, Yang J, Wang W. Chimeric antigen receptor engineered natural killer cells for cancer therapy. Exp Hematol Oncol. 2023;12:70.

Mazinani M, Rahbarizadeh F. New cell sources for CAR-based immunotherapy. Biomarker Res. 2023;11:49.

Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446–8.

Article  CAS  PubMed  Google Scholar 

Han L, Zhang J-S, Zhou J, Zhou K-S, Xu B-L, Li L-L, et al. Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory Multiple Myeloma. Leukemia. 2021;35(10):3002–6.

Article  PubMed  PubMed Central  Google Scholar 

Colamartino ABL, Lemieux W, Bifsha P, Nicoletti S, Chakravarti N, Sanz J, et al. Efficient and robust NK-Cell Transduction with Baboon Envelope Pseudotyped Lentivector. Front Immunol. 2019;10:2873.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu S, Galat V, Galat Y, Lee YKA, Wainwright D, Wu J. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021;14:7.

Wang X, Yang X, Yuan X, Wang W, Wang Y. Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential. Exp Hematol Oncol. 2022;11:85.

Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-Transduced Natural Killer cells in CD19-Positive lymphoid tumors. N Engl J Med. 2020;382(6):545–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520–31.

Article  CAS  PubMed  Google Scholar 

Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14(1):73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu Y, Liu Q, Zhong M, Wang Z, Chen Z, Zhang Y, et al. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies. J Hematol Oncol. 2019;12(1):49.

Article  PubMed  PubMed Central  Google Scholar 

Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-Derived natural killer cells Engineered with chimeric Antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181–92. e5.

Article  CAS  PubMed  PubMed Central  Google Scholar